About
Biosimilar insulins produced via continuous mammalian cell line manufacturing platform
Areas of Focus
Categories
BiosimilarsSeattle/Pacific Northwest
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
4
As Collaborator
4
Total Enrollment
1,208
By Phase
PHASE1: 1PHASE1/PHASE2: 4PHASE2: 2
By Status
RECRUITING: 5TERMINATED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06934382Collaborator
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
PHASE1Recruiting
33 participants
Started: Apr 29, 2025 · Completed: May 30, 2031
NCT06735755Lead Sponsor
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
PHASE1/PHASE2Recruiting
36 participants
Started: Dec 6, 2024 · Completed: Dec 30, 2027
NCT06389877Lead Sponsor
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
PHASE1/PHASE2Recruiting
106 participants
Started: Jun 19, 2024 · Completed: Aug 31, 2027
NCT05885464Lead Sponsor
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
PHASE1/PHASE2Active, not recruiting
5 participants
Started: May 25, 2023 · Completed: Dec 31, 2026
NCT06071377Collaborator
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
N/ARecruiting
1,000 participants
Started: Apr 1, 2023 · Completed: Apr 30, 2026
Locations (1)
Headquarters
Seattle, WA, United States
Map
Loading map...